Effects of Spectator Ligands on the Specific Recognition of Intrastrand Platinum-DNA Cross-links by High Mobility Group Box and TATA-binding Proteins* 210

The results presented describe the effects of various spectator ligands, attached to a platinum 1,2-intrastand d(GpG) cross-link in duplex DNA, on the binding of high mobility group box (HMGB) domains and the TATA-binding protein (TBP). In addition to cisplatin-modified DNA, 15-base pair DNA probes modified by {Pt(1R,2R-diaminocyclohexane)}2+,cis-{Pt(NH3)(cyclohexylamine)}2+, {Pt(ethylenediamine)}2+,cis-{Pt(NH3)(cyclobutylamine)}2+, and cis-{Pt(NH3)(2-picoline)}2+were examined. Electrophoretic mobility shift assays show that both the A and B domains of HMGB1 as well as TBP discriminate between different platinum-DNA adducts. HMGB1 domain A is the most sensitive to the nature of the spectator ligands on platinum. The effect of the spectator ligands on protein binding also depends highly on the base pairs flanking the platinated d(GpG) site. Double-stranded oligonucleotides containing the AG*G*C sequence, where the asterisks denote the sites of platination, with different spectator ligands are only moderately discriminated by the HMGB proteins and TBP, but the recognition of dsTG*G*A is highly dependent on the ligands. The effects of HMGB1 overexpression in a BG-1 ovarian cancer cell line, induced by steroid hormones, on the sensitivity of cells treated with [Pt(1R,2R-diaminocyclohexane)Cl2] andcis-[Pt(NH3)(cyclohexylamine)Cl2] were also examined. The results suggest that HMGB1 protein levels influence the cellular processing ofcis-{Pt(NH3)- (cyclohexylamine)}2+, but not {Pt((1R,2R)-diaminocyclohexane)}2+, DNA lesions. This result is consistent with the observed binding of HMGB1a to platinum-modified dsTG*G*A probes but not with the binding affinity of HMGB1a and HMGB1 to platinum-damaged dsAG*G*C oligonucleotides. These experiments reinforce the importance of sequence context in platinum-DNA lesion recognition by cellular proteins.

[1]  E. Raymond,et al.  Oxaliplatin-induced damage of cellular DNA. , 2000, Molecular pharmacology.

[2]  Seth M. Cohen,et al.  HMG-domain protein recognition of cisplatin 1,2-intrastrand d(GpG) cross-links in purine-rich sequence contexts. , 2000, Biochemistry.

[3]  J. Misset,et al.  Oxaliplatin clinical activity: a review. , 2000, Critical reviews in oncology/hematology.

[4]  S. Lippard,et al.  Stopped-flow fluorescence studies of HMG-domain protein binding to cisplatin-modified DNA. , 2000, Biochemistry.

[5]  S. Lippard,et al.  Enhanced binding of the TATA-binding protein to TATA boxes containing flanking cisplatin 1,2-cross-links. , 2000, Biochemistry.

[6]  S. Lippard,et al.  Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  P. Beale,et al.  Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. , 1999, Journal of inorganic biochemistry.

[8]  J. Turchi,et al.  Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts. , 1999, Biochemistry.

[9]  C. Giandomenico,et al.  Current status of platinum-based antitumor drugs. , 1999, Chemical reviews.

[10]  S. Lippard,et al.  Structure, Recognition, and Processing of Cisplatin-DNA Adducts. , 1999, Chemical reviews.

[11]  A. Aguzzi,et al.  The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice , 1999, Nature Genetics.

[12]  C. Pabo,et al.  Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins , 1999, Nature.

[13]  J. Essigmann,et al.  Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor. , 1998, Biochemistry.

[14]  B. Viollet,et al.  TATA Binding Protein Discriminates between Different Lesions on DNA, Resulting in a Transcription Decrease , 1998, Molecular and Cellular Biology.

[15]  S. Lippard,et al.  Solution Structure of a DNA Duplex Containing a Nitroxide Spin-Labeled Platinum d(GpG) Intrastrand Cross-Link Refined with NMR-Derived Long-Range Electron−Proton Distance Restraints , 1998 .

[16]  P. Sadler,et al.  PKA VALUES OF AQUA LIGANDS OF PLATINUM(II) ANTICANCER COMPLEXES : 1H, 15N AND 195PT NMR STUDIES OF CIS- AND TRANS- PTCL2(NH3)(CYCLOHEXYLAMINE) , 1998 .

[17]  D. Moras,et al.  Cisplatin‐ and UV‐damaged DNA lure the basal transcription factor TFIID/TBP , 1997, The EMBO journal.

[18]  S. Lippard,et al.  DNA sequence context and protein composition modulate HMG-domain protein recognition of cisplatin-modified DNA. , 1997, Biochemistry.

[19]  S. Lippard,et al.  Crystal Structure of the Anticancer Drug Cisplatin Bound to Duplex DNA , 1996 .

[20]  R. Rietbroek,et al.  In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. , 1996, Carcinogenesis.

[21]  T Lagrange,et al.  The general transcription factors of RNA polymerase II. , 1996, Genes & development.

[22]  S. Lippard,et al.  Repair of cisplatin--DNA adducts by the mammalian excision nuclease. , 1996, Biochemistry.

[23]  D. Landsman,et al.  The HMG-1 box protein family: classification and functional relationships. , 1995, Nucleic acids research.

[24]  S. Lippard,et al.  A single HMG domain in high-mobility group 1 protein binds to DNAs as small as 20 base pairs containing the major cisplatin adduct. , 1995, Biochemistry.

[25]  P. Cary,et al.  The Structure of the HMG Box and Its Interaction with DNA , 1995 .

[26]  G. Chu,et al.  Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. , 1994, The Journal of biological chemistry.

[27]  S. Lippard,et al.  DNA binding properties of [Pt(NH3)(C6H11NH2)Cl2], a metabolite of an orally active platinum anticancer drug , 1992 .

[28]  K. Comess,et al.  Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts. , 1992, Biochemistry.

[29]  S. Lippard,et al.  Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. , 1992, Science.

[30]  R. Tarone,et al.  Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[31]  C. Giandomenico,et al.  A convenient preparation of the amminetrichloroplatinate(II) anion , 1987 .

[32]  R. Ozols,et al.  Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. , 1986, The Journal of clinical investigation.

[33]  R. Ozols,et al.  Polyclonal antibodies to quantitate cis-diamminedichloroplatinum(II)--DNA adducts in cancer patients and animal models. , 1985, Environmental health perspectives.

[34]  B. Winograd,et al.  Promising new developments in cancer chemotherapy , 1999, Cancer Chemotherapy and Pharmacology.